Brief: Orion Pharma's ODM-212 Granted Orphan Drug Designation In Mesothelioma
20/04/2026 14:01
April 20 (Reuters) - Orion Oyj ORNBV.HE: REG-ORION PHARMA’S ODM-212 GRANTED ORPHAN DRUG DESIGNATION IN MESOTHELIOMA BY THE US FDA Source text: ID:nGNEDNGzg Further company coverage: ORNBV.HE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))